Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avantor's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avantor's regulatory disclosures and financial reporting.
Avantor reported mixed first-quarter 2026 results with weaker profitability but steady sales and reaffirmed guidance. Net sales were $1,581.4 million, flat with a year earlier, while foreign currency tailwinds meant organic net sales declined 4.1%.
Net income fell to $43.3 million from $64.5 million, and diluted GAAP EPS declined to $0.06 from $0.09. Adjusted net income was $114.0 million versus $155.2 million, with adjusted EPS down to $0.17 from $0.23 and adjusted EBITDA decreasing to $219.4 million, a 13.9% margin versus 17.0%.
Segment results showed lower adjusted operating income in both VWR Distribution & Services and Bioscience & Medtech Products. Operating cash flow was $58.7 million compared with $109.3 million, and free cash flow was $25.2 million versus $82.1 million. As of March 31, 2026, adjusted net leverage was 3.3x. The company reaffirmed its full-year 2026 financial guidance.
Avantor, Inc. announced a leadership transition in its Bioscience & Medtech Products segment. The company hired Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026, to lead growth, operational performance and the Revival Management Office.
The current Executive Vice President, Bioscience and Medtech Products, Benoit Gourdier, will move into a role supporting segment integration activities and is expected to depart the company no later than December 31, 2026. The changes focus on business transformation and integration across Avantor’s enterprise.
Eck Steven W reported acquisition or exercise transactions in this Form 4 filing.
Avantor, Inc. reported that SVP & Chief Accounting Officer Steven W. Eck received an equity grant in the form of restricted stock units. He was awarded 31,645 shares of Common Stock at a stated price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase.
The restricted stock units vest in three equal annual installments beginning on April 3, 2027, tying the award to multi‑year service. After this grant, Eck directly holds 130,978 shares of Avantor common stock, showing his ongoing equity stake in the company.
Avantor, Inc. announced a planned CFO transition and reaffirmed its fiscal 2026 guidance. Executive Vice President and CFO R. Brent Jones will leave the company on or before June 24, 2026, after providing 90 days’ notice under his employment agreement unless waived.
Upon his departure, Senior Vice President and Chief Accounting Officer Steve Eck will serve as interim CFO while continuing as principal accounting officer as the company conducts a search for a permanent CFO. To reflect his expanded responsibilities, Eck will receive an additional $45,000 per month for each month he serves as interim CFO and a one-time $250,000 restricted stock unit award vesting ratably over three years.
The company highlighted Eck’s extensive finance and accounting background and stated that its previously issued fiscal 2026 financial guidance from its fourth quarter 2025 earnings call remains unchanged.
Avantor, Inc. is asking stockholders to vote at a fully virtual annual meeting on May 7, 2026, to elect nine directors, approve executive pay on an advisory basis, set say‑on‑pay frequency, and ratify Deloitte & Touche LLP for 2026.
The proxy highlights major 2025 leadership changes, including the planned transition from former CEO Michael Stubblefield to Emmanuel Ligner and the shift from Jonathan Peacock to independent Chairman Gregory Summe. The Board will shrink from twelve to nine members, with 8 of 9 nominees independent.
Avantor reports 2025 revenue of $6.55 billion, Adjusted EBITDA of $1.07 billion, Adjusted EPS of $0.90, free cash flow of $496 million, and Adjusted Net Leverage of 3.2x. Under Ligner, the company launched the “Avantor Revival” strategy, rebranding VWR as its global distribution channel and resegmenting into VWR Distribution and Services and Bioscience and Medtech Products.
The proxy emphasizes governance features such as an independent chair, annual director elections, majority voting with a resignation policy, proxy access, a 20% special‑meeting right, and prohibitions on short sales, hedging, margin accounts and pledging by insiders. Executive pay is positioned as heavily performance‑based, with clawback policies, strong stock ownership guidelines and no hedging or repricing of underwater options.
Avantor also details an active investor outreach program, noting engagement with holders representing 74% of shares in 2025, and outlines sustainability initiatives, including Science for Goodness, verified climate targets and broader responsible supplier coverage.
Avantor Inc: The Vanguard Group reports zero beneficial ownership of Common Stock following internal realignment
The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Avantor Inc common stock. The filing states an internal realignment caused certain subsidiaries to report beneficial ownership separately in reliance on SEC Release No. 34-39538.
Avantor, Inc. director-associated entity reported a sizable open-market share purchase. A limited liability company linked to director Sanjeev K. Mehra bought 125,000 shares of Avantor common stock on March 10, 2026 at a weighted average price of $8.01 per share, with individual trades ranging from $7.98 to $8.05. Following these purchases, the LLC held 475,000 shares of Avantor common stock indirectly. Separately, Mehra also directly held 8,106 shares after the reported transactions. Mehra disclaims beneficial ownership of the indirectly held securities except to the extent of any pecuniary interest.
Avantor, Inc. executive Claudius Sokenu reported a small share disposition tied to equity compensation taxes. On February 23, 2026, 2,376 shares of common stock at $8.89 per share were withheld by Avantor to cover tax obligations from RSU vesting, leaving him with 252,429 shares directly held.
Avantor, Inc. executive Brittany Hankamer reported two tax-related share dispositions tied to restricted stock unit vesting. On February 23, 2026, 1,324 shares of common stock were withheld at $8.89 per share, and on February 24, 2026, 359 shares were withheld at $9.11 per share to satisfy tax withholding obligations. These were coded as Form 4 transaction code F, indicating payment of tax liability by delivering securities rather than open-market sales. After these withholdings, Hankamer directly owned 249,045 shares of Avantor common stock.